NASDAQ:ITCI - Intra-Cellular Therapies Stock Price, Price Target & More

$19.46 -0.44 (-2.21 %)
(As of 04/19/2018 04:00 PM ET)
Previous Close$19.46
Today's Range$19.20 - $19.94
52-Week Range$7.85 - $25.82
Volume297,025 shs
Average Volume537,965 shs
Market Capitalization$1.11 billion
P/E Ratio-9.18
Dividend YieldN/A
Beta0.59

About Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies logoIntra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. It is also developing ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Receive ITCI News and Ratings via Email

Sign-up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ITCI
CUSIPN/A
Phone212-923-3344

Debt

Debt-to-Equity RatioN/A
Current Ratio33.04%
Quick Ratio33.04%

Price-To-Earnings

Trailing P/E Ratio-9.18
Forward P/E Ratio-5.84
P/E GrowthN/A

Sales & Book Value

Annual Sales$250,000.00
Price / Sales4,256.29
Cash FlowN/A
Price / CashN/A
Book Value$8.33 per share
Price / Book2.34

Profitability

EPS (Most Recent Fiscal Year)($2.12)
Net Income$-97,770,000.00
Net Margins-39,745.53%
Return on Equity-26.67%
Return on Assets-25.60%

Miscellaneous

Employees49
Outstanding Shares54,680,000

How to Become a New Pot Stock Millionaire

Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies Inc (NASDAQ:ITCI) issued its quarterly earnings results on Thursday, March, 1st. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.06. The biopharmaceutical company had revenue of $5.06 million for the quarter, compared to analyst estimates of $0.05 million. Intra-Cellular Therapies had a negative return on equity of 26.67% and a negative net margin of 39,745.53%. The business's revenue was down 94.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.64) EPS. View Intra-Cellular Therapies' Earnings History.

When is Intra-Cellular Therapies' next earnings date?

Intra-Cellular Therapies is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Intra-Cellular Therapies.

What price target have analysts set for ITCI?

11 brokerages have issued 12-month price targets for Intra-Cellular Therapies' stock. Their forecasts range from $24.00 to $36.00. On average, they anticipate Intra-Cellular Therapies' share price to reach $29.10 in the next twelve months. View Analyst Ratings for Intra-Cellular Therapies.

What are Wall Street analysts saying about Intra-Cellular Therapies stock?

Here are some recent quotes from research analysts about Intra-Cellular Therapies stock:
  • 1. According to Zacks Investment Research, "Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York. " (3/6/2018)
  • 2. Cantor Fitzgerald analysts commented, "Lumateperone NDA filing still expected in mid-2018. We view the pre- NDA meeting (and what may be said thereafter), the actual filing and the FDA acceptance of it (presumably) as minor events that are expected and not stock moving." (3/1/2018)
  • 3. SunTrust Banks analysts commented, "Meeting with FDA could help identify the path forward for ralinepag. On the 3Q17 results conference call, management commented that the company will seek a meeting with the FDA to determine the pivotal development plan for ralinepag. Specific timing of the meeting is pending FDA scheduling but management laid out their views on the drug candidate’s development program. Key considerations include 1) accelerating time to market, 2) maximizing the breadth and scope of label, 3) raising physician awareness of the compound and 4) comparing ralinepag with other available treatments." (11/8/2017)

Who are some of Intra-Cellular Therapies' key competitors?

Who are Intra-Cellular Therapies' key executives?

Intra-Cellular Therapies' management team includes the folowing people:
  • Dr. Sharon Mates Ph.D., Co-Founder, Chairman, CEO & Pres (Age 65)
  • Mr. Lawrence J. Hineline CPA, VP of Fin., CFO, Treasurer & Assistant Sec. (Age 62)
  • Dr. Robert E. Davis Ph.D., Sr. VP & Chief Scientific Officer (Age 67)
  • Mr. Michael I. Halstead J.D., Sr. VP, Gen. Counsel, Corp. Compliance Officer & Sec. (Age 45)
  • Dr. Kimberly E. Vanover Ph.D., Sr. VP of Clinical Devel. (Age 52)

Has Intra-Cellular Therapies been receiving favorable news coverage?

Press coverage about ITCI stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Intra-Cellular Therapies earned a media sentiment score of 0.07 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 45.03 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $19.46.

How big of a company is Intra-Cellular Therapies?

Intra-Cellular Therapies has a market capitalization of $1.11 billion and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-97,770,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis. Intra-Cellular Therapies employs 49 workers across the globe.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-923-3344 or via email at [email protected]


MarketBeat Community Rating for Intra-Cellular Therapies (ITCI)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  291 (Vote Outperform)
Underperform Votes:  180 (Vote Underperform)
Total Votes:  471
MarketBeat's community ratings are surveys of what our community members think about Intra-Cellular Therapies and other stocks. Vote "Outperform" if you believe ITCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ITCI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Intra-Cellular Therapies (NASDAQ:ITCI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Intra-Cellular Therapies in the last 12 months. Their average twelve-month price target is $29.10, suggesting that the stock has a possible upside of 49.54%. The high price target for ITCI is $36.00 and the low price target for ITCI is $24.00. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.912.912.892.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.10$27.80$26.75$26.1429
Price Target Upside: 49.54% upside11.65% upside79.53% upside22.22% upside

Intra-Cellular Therapies (NASDAQ:ITCI) Consensus Price Target History

Price Target History for Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies (NASDAQ:ITCI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/3/2018Leerink SwannSet Price TargetBuy$25.00HighView Rating Details
4/2/2018Canaccord GenuitySet Price TargetBuy$31.00LowView Rating Details
3/2/2018SunTrust BanksReiterated RatingBuy$28.00LowView Rating Details
3/2/2018CowenReiterated RatingBuy$28.00HighView Rating Details
3/1/2018Cantor FitzgeraldReiterated RatingBuy$28.00HighView Rating Details
2/26/2018JPMorgan ChaseInitiated CoverageOverweight -> Overweight$25.00HighView Rating Details
2/8/2018Royal Bank of CanadaInitiated CoverageOutperform -> Outperform$33.00MediumView Rating Details
9/8/2017BTIG ResearchReiterated RatingBuy$36.00MediumView Rating Details
9/7/2017Piper JaffrayUpgradeNeutral -> Overweight$14.00 -> $33.00HighView Rating Details
8/24/2017JMP SecuritiesUpgradeMarket Perform -> Outperform$24.00HighView Rating Details
5/2/2017Ladenburg ThalmannDowngradeBuy -> NeutralHighView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Intra-Cellular Therapies (NASDAQ:ITCI) Earnings History and Estimates Chart

Earnings by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies (NASDAQ:ITCI) Earnings Estimates

2018 EPS Consensus Estimate: ($2.70)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.62)($0.62)($0.62)
Q2 20181($0.64)($0.64)($0.64)
Q3 20181($0.70)($0.70)($0.70)
Q4 20181($0.74)($0.74)($0.74)

Intra-Cellular Therapies (NASDAQ ITCI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018        
3/1/2018n/a($0.50)($0.56)$0.05 million$5.06 millionViewN/AView Earnings Details
11/8/2017Q3 2017($0.53)($0.5270)$0.06 million$0.03 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.74)($0.41)$0.03 million$0.11 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.74)($0.62)$0.02 million$0.10 millionViewN/AView Earnings Details
3/1/2017Q4 2016($0.77)($0.64)$0.10 million$0.10 millionViewListenView Earnings Details
11/9/2016Q316($0.84)($0.70)$0.04 million$4.36 millionViewListenView Earnings Details
8/4/2016Q216($0.79)($0.71)$0.02 million$0.23 millionViewN/AView Earnings Details
4/28/2016Q116($0.78)($0.64)$0.02 millionViewListenView Earnings Details
2/25/2016Q415($0.84)($0.67)$0.05 million$30.66 millionViewListenView Earnings Details
11/5/2015Q315($0.66)($0.91)$0.10 millionViewN/AView Earnings Details
8/5/2015Q215($0.72)($0.61)$40.00 million$57.40 millionViewN/AView Earnings Details
4/30/2015Q1($0.68)($0.72)ViewN/AView Earnings Details
3/12/2015Q4 2014($0.49)($0.52)$0.07 millionViewN/AView Earnings Details
11/3/2014Q314($0.34)($0.22)$0.12 millionViewN/AView Earnings Details
8/12/2014Q214($0.24)($0.15)$0.22 millionViewN/AView Earnings Details
5/5/2014Q1 2014($0.23)($0.17)$0.17 millionViewN/AView Earnings Details
3/26/2014($0.41)($0.36)$0.60 million$0.83 millionViewN/AView Earnings Details
11/5/2013Q3 2013($0.23)($0.42)$0.67 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Intra-Cellular Therapies (NASDAQ:ITCI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Intra-Cellular Therapies (NASDAQ ITCI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.80%
Institutional Ownership Percentage: 70.47%
Insider Trading History for Intra-Cellular Therapies (NASDAQ:ITCI)
Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies (NASDAQ ITCI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/16/2018Lawrence J HinelineVPSell49,700$20.02$994,994.00View SEC Filing  
1/22/2018Michael HalsteadSVPSell25,500$18.03$459,765.00191View SEC Filing  
1/8/2018Kimberly E VanoverSVPSell772$17.46$13,479.1212,373View SEC Filing  
1/8/2018Sharon MatesChairmanSell6,604$17.48$115,437.921,088,707View SEC Filing  
1/5/2018Kimberly E VanoverSVPSell1,185$17.37$20,583.4526,803View SEC Filing  
1/5/2018Sharon MatesChairmanSell11,257$17.08$192,269.561,099,964View SEC Filing  
1/4/2018Lawrence J HinelineCFOSell3,192$15.67$50,018.6468,686View SEC Filing  
12/29/2017Christopher D AlafiDirectorBuy1,001$14.48$14,494.48View SEC Filing  
12/11/2017Richard A LernerDirectorSell7,000$15.09$105,630.008,621View SEC Filing  
12/5/2017Robert E DavisSVPSell650$15.00$9,750.0028,514View SEC Filing  
11/22/2017Christopher D AlafiDirectorBuy10,000$15.55$155,500.00744,466View SEC Filing  
10/30/2017Sharon MatesCEOSell18,750$15.75$295,312.501,107,457View SEC Filing  
10/2/2017Alafi Capital Co LlcMajor ShareholderBuy258,065$15.50$4,000,007.503,953,270View SEC Filing  
1/5/2017Lawrence J HinelineVPSell1,918$16.58$31,800.4463,389View SEC Filing  
1/5/2017Michael HalsteadSVPSell1,601$16.55$26,496.5521,506View SEC Filing  
1/5/2017Sharon MatesChairmanSell4,081$16.55$67,540.551,088,707View SEC Filing  
12/15/2016Kimberly E VanoverSVPSell9,375$15.23$142,781.255,000View SEC Filing  
12/7/2016Alafi Capital Co LlcMajor ShareholderBuy65,000$16.27$1,057,550.003,674,379View SEC Filing  
11/14/2016Christopher D AlafiDirectorBuy34,000$14.50$493,000.00730,529View SEC Filing  
2/29/2016Christopher D AlafiDirectorBuy100,000$29.70$2,970,000.00728,828View SEC Filing  
12/15/2015Lawrence J. HinelineCFOSell45,000$51.45$2,315,250.0062,200View SEC Filing  
12/11/2015Sharon MatesCEOSell51,500$53.87$2,774,305.001,086,185View SEC Filing  
12/8/2015Joel S MarcusDirectorSell92,700$54.47$5,049,369.0018,722View SEC Filing  
11/24/2015Lawrence J HinelineCFOSell5,000$55.00$275,000.0059,700View SEC Filing  
6/8/2015Lawrence P WennogleVPSell25,000$26.84$671,000.00View SEC Filing  
3/11/2015Christopher D AlafiDirectorBuy625,000$24.00$15,000,000.00View SEC Filing  
12/9/2014Lawrence J HinelineCFOSell22,500$16.71$375,975.00View SEC Filing  
12/1/2014Moshe AlafiMajor ShareholderBuy1,422$14.75$20,974.50View SEC Filing  
11/28/2014Christopher D AlafiDirectorBuy35,000$14.75$516,250.00View SEC Filing  
11/19/2014Alafi Capital Co LlcMajor ShareholderBuy1,034$14.25$14,734.50View SEC Filing  
11/18/2014Alafi Capital Co LlcMajor ShareholderBuy3,664$14.26$52,248.64View SEC Filing  
11/13/2014Alafi Capital Co LlcMajor ShareholderBuy12,200$15.34$187,148.00View SEC Filing  
11/6/2014Michael HalsteadSVPBuy20,000$15.38$307,600.00View SEC Filing  
10/15/2014Lawrence P WennogleVPSell3,604$15.00$54,060.00View SEC Filing  
10/13/2014Lawrence P WennogleVPSell1,600$15.00$24,000.00View SEC Filing  
10/8/2014Lawrence P WennogleVPSell4,745$15.00$71,175.00View SEC Filing  
10/6/2014Lawrence P WennogleVPSell16,499$15.00$247,485.00View SEC Filing  
9/15/2014Lawrence P WennogleVPSell5,000$15.00$75,000.00View SEC Filing  
9/8/2014Lawrence J HinelineCFOSell300$15.00$4,500.00View SEC Filing  
5/22/2014Lawrence P WennogleVPSell6,000$15.00$90,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Intra-Cellular Therapies (NASDAQ ITCI) News Headlines

Source:
DateHeadline
Traders Buy Large Volume of Call Options on Intra-Cellular Therapies (ITCI)Traders Buy Large Volume of Call Options on Intra-Cellular Therapies (ITCI)
www.americanbankingnews.com - April 19 at 8:32 AM
Intra-Cellular Therapies Sees Unusually Large Options Volume (ITCI)Intra-Cellular Therapies Sees Unusually Large Options Volume (ITCI)
www.americanbankingnews.com - April 19 at 8:32 AM
Notable Tuesday Option Activity: ALGN, TWTR, ITCINotable Tuesday Option Activity: ALGN, TWTR, ITCI
www.nasdaq.com - April 17 at 5:42 PM
Intra-Cellular Therapies Inc (ITCI) Receives Consensus Recommendation of "Buy" from AnalystsIntra-Cellular Therapies Inc (ITCI) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 11 at 7:35 PM
Intra-Cellular Therapies (ITCI) Given a $10.00 Price Target at Piper JaffrayIntra-Cellular Therapies (ITCI) Given a $10.00 Price Target at Piper Jaffray
www.americanbankingnews.com - April 10 at 10:31 PM
Intra-Cellular Therapies (ITCI) Upgraded to "Buy" by Zacks Investment ResearchIntra-Cellular Therapies (ITCI) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - April 10 at 1:11 PM
Intra-Cellular Therapies (ITCI) Downgraded by Zacks Investment Research to "Hold"Intra-Cellular Therapies (ITCI) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 7 at 11:22 AM
Intra-Cellular Therapies Inc (ITCI) to Post FY2020 Earnings of ($2.01) Per Share, Leerink Swann ForecastsIntra-Cellular Therapies Inc (ITCI) to Post FY2020 Earnings of ($2.01) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - April 5 at 9:17 AM
Pre-Market Technical Scan on Biotech Equities -- INSYS Therapeutics, Intellia Therapeutics, Intercept Pharma, and ...Pre-Market Technical Scan on Biotech Equities -- INSYS Therapeutics, Intellia Therapeutics, Intercept Pharma, and ...
www.prnewswire.com - April 4 at 4:01 PM
Intra-Cellular Therapies (ITCI) Given a $25.00 Price Target at Leerink SwannIntra-Cellular Therapies (ITCI) Given a $25.00 Price Target at Leerink Swann
www.americanbankingnews.com - April 4 at 8:04 AM
Canaccord Genuity Analysts Give Intra-Cellular Therapies (ITCI) a $31.00 Price TargetCanaccord Genuity Analysts Give Intra-Cellular Therapies (ITCI) a $31.00 Price Target
www.americanbankingnews.com - April 3 at 10:36 AM
Here's Why Alkermes plc and Intra-Cellular Therapies, Inc. Are Crashing TodayHere's Why Alkermes plc and Intra-Cellular Therapies, Inc. Are Crashing Today
finance.yahoo.com - April 2 at 5:14 PM
Pre-Market Technical Scan on Biotech Equities -- INSYS Therapeutics, Intellia Therapeutics, Intercept Pharma, and Intra-Cellular TherapiesPre-Market Technical Scan on Biotech Equities -- INSYS Therapeutics, Intellia Therapeutics, Intercept Pharma, and Intra-Cellular Therapies
www.bizjournals.com - April 2 at 9:00 AM
Intra-Cellular down 7% premarket on FDA rejection of Alkermes application for MDD med ALKS 5461Intra-Cellular down 7% premarket on FDA rejection of Alkermes' application for MDD med ALKS 5461
seekingalpha.com - April 2 at 9:00 AM
Intra-Cellular Therapies (ITCI) Stock Rating Upgraded by Zacks Investment ResearchIntra-Cellular Therapies (ITCI) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 1 at 1:36 PM
SunTrust Banks Upgrades Intra-Cellular Therapies (ITCI) to BuySunTrust Banks Upgrades Intra-Cellular Therapies (ITCI) to Buy
www.americanbankingnews.com - April 1 at 9:46 AM
BidaskClub Downgrades Intra-Cellular Therapies (ITCI) to HoldBidaskClub Downgrades Intra-Cellular Therapies (ITCI) to Hold
www.americanbankingnews.com - March 30 at 11:07 AM
Intra-Cellular Therapies (ITCI) Downgraded to Hold at Zacks Investment ResearchIntra-Cellular Therapies (ITCI) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - March 26 at 10:58 PM
Intra-Cellular Therapies (ITCI) Rating Lowered to Sell at Zacks Investment ResearchIntra-Cellular Therapies (ITCI) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 24 at 1:37 PM
Intra-Cellular Therapies Inc (ITCI) Given Consensus Rating of "Buy" by BrokeragesIntra-Cellular Therapies Inc (ITCI) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 17 at 7:38 PM
Intra-Cellular Therapies (ITCI) Lifted to Buy at BidaskClubIntra-Cellular Therapies (ITCI) Lifted to Buy at BidaskClub
www.americanbankingnews.com - March 17 at 5:36 PM
Wired News – FDA Approved Intra-Cellular’s Rolling NDA Submission for Lumateperone for SchizophreniaWired News – FDA Approved Intra-Cellular’s Rolling NDA Submission for Lumateperone for Schizophrenia
finance.yahoo.com - March 15 at 8:33 AM
Intra-Cellular Therapies (ITCI) Announces Positive Pre-NDA Meeting with FDA for LumateperoneIntra-Cellular Therapies (ITCI) Announces Positive Pre-NDA Meeting with FDA for Lumateperone
www.streetinsider.com - March 13 at 7:05 PM
Canaccord Genuity Reiterates $31.00 Price Target for Intra-Cellular Therapies (ITCI)Canaccord Genuity Reiterates $31.00 Price Target for Intra-Cellular Therapies (ITCI)
www.americanbankingnews.com - March 13 at 3:46 PM
Intra-Cellular Therapies (ITCI) Announces Positive Pre-NDA Meeting with FDA for Lumateperone - StreetInsider.comIntra-Cellular Therapies (ITCI) Announces Positive Pre-NDA Meeting with FDA for Lumateperone - StreetInsider.com
www.streetinsider.com - March 13 at 8:43 AM
Intra-Cellular Therapies Announces Positive Pre-NDA Meeting with FDA for Lumateperone for the Treatment of SchizophreniaIntra-Cellular Therapies Announces Positive Pre-NDA Meeting with FDA for Lumateperone for the Treatment of Schizophrenia
finance.yahoo.com - March 13 at 8:43 AM
Intra-Cellular Therapies (ITCI) Upgraded at ValuEngineIntra-Cellular Therapies (ITCI) Upgraded at ValuEngine
www.americanbankingnews.com - March 11 at 2:23 PM
Intra-Cellular Therapies Inc Forecasted to Earn FY2018 Earnings of ($3.95) Per Share (ITCI)Intra-Cellular Therapies Inc Forecasted to Earn FY2018 Earnings of ($3.95) Per Share (ITCI)
www.americanbankingnews.com - March 7 at 11:51 AM
Intra-Cellular Therapies (ITCI) "Outperform" Rating Reaffirmed at Leerink SwannIntra-Cellular Therapies' (ITCI) "Outperform" Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - March 7 at 10:59 AM
Intra-Cellular Therapies Inc (ITCI) Expected to Earn Q1 2018 Earnings of ($0.62) Per ShareIntra-Cellular Therapies Inc (ITCI) Expected to Earn Q1 2018 Earnings of ($0.62) Per Share
www.americanbankingnews.com - March 7 at 7:55 AM
Equities Analysts Set Expectations for Intra-Cellular Therapies Incs FY2019 Earnings (ITCI)Equities Analysts Set Expectations for Intra-Cellular Therapies Inc's FY2019 Earnings (ITCI)
www.americanbankingnews.com - March 6 at 2:25 PM
SunTrust Banks Weighs in on Intra-Cellular Therapies Incs FY2022 Earnings (ITCI)SunTrust Banks Weighs in on Intra-Cellular Therapies Inc's FY2022 Earnings (ITCI)
www.americanbankingnews.com - March 5 at 9:50 AM
Intra-Cellular Therapies Inc to Post Q1 2018 Earnings of ($0.62) Per Share, Leerink Swann Forecasts (ITCI)Intra-Cellular Therapies Inc to Post Q1 2018 Earnings of ($0.62) Per Share, Leerink Swann Forecasts (ITCI)
www.americanbankingnews.com - March 5 at 2:08 AM
Intra-Cellular Therapies (ITCI) Given Buy Rating at CowenIntra-Cellular Therapies (ITCI) Given Buy Rating at Cowen
www.americanbankingnews.com - March 3 at 8:22 PM
Intra-Cellular Therapies (ITCI) Rating Reiterated by SunTrust BanksIntra-Cellular Therapies (ITCI) Rating Reiterated by SunTrust Banks
www.americanbankingnews.com - March 2 at 4:22 PM
Intra-Cellular Therapies (ITCI) Buy Rating Reiterated at Cantor FitzgeraldIntra-Cellular Therapies' (ITCI) Buy Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - March 1 at 8:13 PM
Intra-Cellular Therapies (ITCI) Announces Quarterly  Earnings Results, Misses Estimates By $0.06 EPSIntra-Cellular Therapies (ITCI) Announces Quarterly Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - March 1 at 1:56 PM
Intra-Cellular Therapies reports Q4 resultsIntra-Cellular Therapies reports Q4 results
seekingalpha.com - March 1 at 9:43 AM
Intra-Cellular Therapies (ITCI) Now Covered by JPMorgan Chase & Co.Intra-Cellular Therapies (ITCI) Now Covered by JPMorgan Chase & Co.
www.americanbankingnews.com - February 26 at 2:20 PM
Intra-Cellular Therapies (ITCI) Scheduled to Post Earnings on ThursdayIntra-Cellular Therapies (ITCI) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - February 23 at 5:26 PM
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and WebcastIntra-Cellular Therapies to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast
finance.yahoo.com - February 22 at 8:34 AM
Intra-Cellular Therapies Inc (ITCI) Receives Average Rating of "Buy" from AnalystsIntra-Cellular Therapies Inc (ITCI) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - February 20 at 7:46 PM
Lawrence J. Hineline Sells 49,700 Shares of Intra-Cellular Therapies Inc (ITCI) StockLawrence J. Hineline Sells 49,700 Shares of Intra-Cellular Therapies Inc (ITCI) Stock
www.americanbankingnews.com - February 20 at 6:40 PM
Intra-Cellular Therapies (ITCI) Upgraded to Sell by BidaskClubIntra-Cellular Therapies (ITCI) Upgraded to Sell by BidaskClub
www.americanbankingnews.com - February 19 at 3:56 PM
UPDATE - Intra-Cellular Therapies to Present at RBC Capital Markets 2018 Global Healthcare ConferenceUPDATE - Intra-Cellular Therapies to Present at RBC Capital Markets 2018 Global Healthcare Conference
finance.yahoo.com - February 15 at 5:10 PM
Intra-Cellular Therapies (ITCI) Now Covered by Royal Bank of CanadaIntra-Cellular Therapies (ITCI) Now Covered by Royal Bank of Canada
www.americanbankingnews.com - February 11 at 3:24 PM
Intra-Cellular Therapies to Present at Upcoming Investor ConferencesIntra-Cellular Therapies to Present at Upcoming Investor Conferences
finance.yahoo.com - February 7 at 9:52 AM
Intra-Cellular Therapies (ITCI) Cut to "Strong Sell" at BidaskClubIntra-Cellular Therapies (ITCI) Cut to "Strong Sell" at BidaskClub
www.americanbankingnews.com - February 3 at 2:44 PM
Financial Contrast: Intra-Cellular Therapies (ITCI) and Mast Therapeutics (SVRA)Financial Contrast: Intra-Cellular Therapies (ITCI) and Mast Therapeutics (SVRA)
www.americanbankingnews.com - February 3 at 1:12 AM
Intra-Cellular Therapies Inc (ITCI) Short Interest UpdateIntra-Cellular Therapies Inc (ITCI) Short Interest Update
www.americanbankingnews.com - January 27 at 2:32 AM

SEC Filings

Intra-Cellular Therapies (NASDAQ:ITCI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Intra-Cellular Therapies (NASDAQ:ITCI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Intra-Cellular Therapies (NASDAQ ITCI) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.